
Tau (AT8); Phospho Tau (Ser 202, Thr 205) - ALZFORUM
Feb 6, 2024 · Hyperphosphorylated tau polymerizes into paired helical filaments, which aggregate to form neurofibrillary tangles, one of the defining lesions of Alzheimer’s disease. Recognizes paired …
Triple Trouble: New Knock-in Turbocharges Tauopathy
May 1, 2025 · They accumulated hyperphosphorylated tau in their brains and lost synapses by approximately 15 months of age, but they had no tau oligomers capable of seeding aggregates. …
301 Moved Permanently
Moved PermanentlyThe document has moved here.
Tau (PHF-1) | ALZFORUM
Feb 5, 2024 · Recognizes tau doubly phosphorylated at serines 396 and 404 Immunoreactivity seen in Alzheimer's disease and other tauopathies but not controls Used to assess the progression of tau …
ApoE3 Christchurch Clings Tightly to Tau, Averting Tangles
Feb 1, 2025 · To find out, the scientists turned to surface plasmon resonance, a technique that quantifies molecular interactions in real time. It showed that ApoE3Ch clings onto tau monomers …
LY3954068 | ALZFORUM
Nov 25, 2024 · LY3954068 is a small interfering RNA (siRNA) that targets expression of the microtubule-associated binding protein tau. No information is available about the makeup of LY3954068.
Tau (CP-13) - ALZFORUM
Feb 7, 2024 · This monoclonal antibody, generated against paired helical filaments (PHFs) isolated from Alzheimer’s brains, recognizes tau phosphorylated at serine 202. Recognizes tau phosphorylated at …
A Tale of Two T Cells—Slowing Tau Spread, Shredding White Matter
Jul 11, 2025 · With T cells sidelined in these CD8 knockouts, tau pathology went on the offensive. By 30 weeks of age, phospho-tau had spread deeper into the brain than in CD8-intact controls (image …
Plasma p-Tau217 Flags Alzheimer’s Pathology in Other Disorders
Feb 20, 2025 · Plasma p-Tau217 detects AD co-pathology in FTD patients with high accuracy. FTD patients with AD co-pathology performed worse on memory tests. The marker identifies people who …
Gosuranemab - ALZFORUM
Full trial results, published after peer review, confirmed that gosuranemab reduced CSF unbound N-terminal tau fragments by 98 percent, but did not change other exploratory biomarkers, or primary or …